71 deals worth $12.9B reported in May 2023: Global Data

In May 2024, the healthcare industry reported 71 deals worth $12.9 billion, compared to the last 12-month (May 2023 to April 2024) average of 99 deals worth $19.2 billion.

Merck & Co, to acquire Eyebiotech, a clinical-stage ophthalmology biotechnology company, for a potential value of $3 billion; Biogen to acquire Human Immunology Biosciences, a biotechnology company, for a consideration of approximately $1.8 billion; and Novartis AG to acquire  Mariana Oncology, a preclinical-stage biotechnology company for an approximate consideration of $1.7 billion. These were the three major deals that contributed 51 per cent of the total deal value during May 2024.

The healthcare industry reported 97 venture capital (VC) deals worth $3 billion in May 2024, compared to the last 12-month (May 2023 to April 2024) average of 110 deals worth $2.7 billion.

AltruBio, a clinical stage biotechnology company raising $225 million in series B financing to advance the clinical development of novel immune checkpoint enhancer program; Zenas BioPharma (USA), a biopharmaceutical company, raising $200 million in series C financing to advance mid and late-stage immunology-focused clinical development programs; TheRas, d/b/a BridgeBio Oncology Therapeutics, raising $200 million in financing to accelerate the development of its novel precision oncology pipeline. These were the three major VC deals reported in May 2024.